Literature DB >> 22588167

An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals.

Michael Stensland1, Peter R Watson, Kyle L Grazier.   

Abstract

OBJECTIVE: Hospitalization is a critical component of treatment for individuals with serious and persistent mental illness. Despite its resource intensity, the costs of inpatient psychiatric hospitalizations in the United States are not well understood. The objective of this research was to provide cost estimates for inpatient psychiatric care.
METHODS: Using Premier's Perspective Comparative Database, supplemented with the MarketScan database, this study estimated the average charges, cost to provide care, and amount of reimbursement for inpatient psychiatric care in 418 community-based hospitals in 2006 (N=261,996 hospitalizations).
RESULTS: Charges were 2.5 times higher than the hospitals' reported costs to deliver care. Reimbursed amounts indicated by MarketScan were similar to the reported costs to deliver care. The average cost to deliver care was highest for Medicare and lowest for the uninsured: schizophrenia treatment, $8,509 for 11.1 days and $5,707 for 7.4 days, respectively; bipolar disorder treatment, $7,593 for 9.4 days and $4,356 for 5.5 days; depression treatment, $6,990 for 8.4 days and $3,616 for 4.4 days; drug use disorder treatment, $4,591 for 5.2 days and $3,422 for 3.7 days; and alcohol use disorder treatment, $5,908 for 6.2 days and $4,147 for 3.8 days.
CONCLUSIONS: Consistent with past research, the results suggest that previous attempts to control pricing may have led to unintended consequences, including a large gap between charges and reimbursed amounts, potential cost shifting between payers, and potentially extended lengths of stay to offset reduced per diems. The lack of transparency in pricing makes it challenging to estimate the cost to society for a day of psychiatric hospitalization.

Entities:  

Mesh:

Year:  2012        PMID: 22588167     DOI: 10.1176/appi.ps.201100402

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  19 in total

1.  PerserisTM: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.

Authors:  Andrew Karas; Gary Burdge; Jose A Rey
Journal:  P T       Date:  2019-08

Review 2.  The Cost of Relapse in Schizophrenia.

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

3.  When Home is Still Unsafe: From Family Reunification to Foster Care Reentry.

Authors:  Sarah Font; Kierra Sattler; Elizabeth Gershoff
Journal:  J Marriage Fam       Date:  2018-05-18

4.  Cost-effectiveness of In-Home Cognitive Behavioral Therapy for low-income depressed mothers participating in early childhood prevention programs.

Authors:  Robert T Ammerman; Peter J Mallow; John A Rizzo; Frank W Putnam; Judith B Van Ginkel
Journal:  J Affect Disord       Date:  2016-11-03       Impact factor: 4.839

5.  Depressive Disorder Related Hospitalizations in Portugal Between 2008-2015: a Nationwide Observational Study.

Authors:  Manuel Gonçalves-Pinho; João Pedro Ribeiro; Lia Fernandes; Alberto Freitas
Journal:  Psychiatr Q       Date:  2022-06-21

6.  Economic Burden of Treatment-Resistant Depression Among Patients Hospitalized for Major Depressive Disorder in the United States.

Authors:  Jay Lin; Holly Szukis; John J Sheehan; Larry Alphs; Brandy Menges; Melissa Lingohr-Smith; Carmela Benson
Journal:  Psychiatr Res Clin Pract       Date:  2019-10-11

7.  Illness severity and psychiatric hospitalization rates among Asian Americans and Pacific Islanders.

Authors:  Tetine Sentell; George Jay Unick; Hyeong Jun Ahn; Kathryn L Braun; Jill Miyamura; Martha Shumway
Journal:  Psychiatr Serv       Date:  2013-11-01       Impact factor: 3.084

8.  Rapid Adoption and Implementation of Telehealth Group Psychotherapy During COVID 19: Practical Strategies and Recommendations.

Authors:  Ajeng J Puspitasari; Dagoberto Heredia; Melanie Gentry; Craig Sawchuk; Bernie Theobald; Wendy Moore; Michael Tiede; Christine Galardy; Kathryn Schak; Mayo Clinic
Journal:  Cogn Behav Pract       Date:  2021-06-24

9.  The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.

Authors:  William Montgomery; Li Liu; Michael D Stensland; Hai Bo Xue; Tamas Treuer; Haya Ascher-Svanum
Journal:  Clinicoecon Outcomes Res       Date:  2013-08-14

10.  Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data.

Authors:  Xiaoli Niu; Syvart Dennen; Carole Dembek; Kimberly Laubmeier; Yanmei Liu; Phani Veeranki; Michael Tocco; G Rhys Williams
Journal:  Curr Ther Res Clin Exp       Date:  2021-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.